Printer Friendly

TELOR OPHTHALMIC PHARMACEUTICALS, INC. INITIATES PHASE II CLINICAL TRIALS TO EVALUATE TEKRON AS A NEW TREATMENT FOR GLAUCOMA

 WOBURN, Mass., July 29 /PRNewswire/ -- Telor Ophthalmic Pharmaceuticals, Inc. (NASDAQ-NMS: TELR) announced today that it has initiated Phase II clinical trials with TEKRON(tm), a product it is developing for use in controlling elevated intraocular pressure associated with glaucoma and ocular hypertension. Fluid flows in and out of the eye, exerting pressure which maintains the eye's shape, provides nutrients and removes waste products. Elevated intraocular pressure results from poor drainage of the intraocular fluid from the eye. TEKRON, intended to address the source of the condition by increasing fluid outflow from the eye, is being developed for potential use as a topical once-a-day ophthalmic pharmaceutical product. Most existing glaucoma therapies act indirectly by suppressing fluid inflow. Approximately 1.5 to 2 million Americans are currently receiving treatment for glaucoma and ocular hypertension.
 "The start of Phase II trials is a significant step in the clinical development of TEKRON," said Stephen J. Riggi, Ph.D., president and chief executive officer of Telor Ophthalmic Pharmaceuticals. "We believe that TEKRON represents a novel approach to the treatment of elevated intraocular pressure associated with glaucoma and ocular hypertension. The company believes that TEKRON may require only single daily dosage, and may offer other advantages over existing therapies." Drawbacks associated with current glaucoma treatments include lack of patient compliance due to the need to administer medication several times daily as well as the potential for local and systemic side effects.
 The recently commenced clinical trials are double-masked, placebo- controlled Phase II studies to assess, among other things, the safety and efficacy of TEKRON over a range of doses in patients with glaucoma and ocular hypertension. Patients will receive TEKRON once-a-day and intraocular pressure will be measured daily using standard medical techniques.
 "The results of Phase I trials completed earlier this year demonstrate that TEKRON is safe at several doses," said Arthur H. Neufeld, Ph.D., chief scientific officer of Telor. "Preclinical studies in animals with induced glaucoma showed that TEKRON can safely and effectively control elevated intraocular pressure. While the glaucoma animal model is not identical to the human disease, we are extremely encouraged by those results."
 TEKRON is designed to address the underlying cause of elevated intraocular pressure, decreased outflow from the eye, by increasing fluid outflow through the trabecular meshwork of the eye. TEKRON is a formulation of ethacrynic acid, a systemic drug which has been used for over 20 years for the treatment of fluid retention resulting from congestive heart failure, cirrhosis of the liver, and kidney disease. Telor has an exclusive worldwide license from the Massachusetts Eye and Ear Infirmary to patents issued in the United States, Canada, Australia, and Europe and pending elsewhere covering the use of ethacrynic acid to lower elevated intraocular pressure. TEKRON is a trademark of Telor.
 Telor is an ophthalmic pharmaceutical company dedicated to the development and marketing of innovative prescription pharmaceuticals for use in the treatment of age-related eye diseases and in ophthalmic surgery. The company's goal is to introduce into the worldwide ophthalmic pharmaceuticals market a broad portfolio of patent-protected products that are based on novel mechanisms of action and that offer significant improvements over existing therapies.
 The company's lead products in clinical development are TEKRON(tm), a potential product for topical use in controlling chronic elevated intraocular pressure associated with glaucoma and ocular hypertension, and XARANO(tm), a potential product for use during cataract surgery to prevent or reduce transient post-operative increases in intraocular pressure. In addition, clinical studies are underway to assess the feasibility of a pharmaceutical approach to the treatment of presbyopia, an age-related impairment of the ability of the eye to focus on near objects. Telor has its headquarters in Woburn, Mass.
 -0- 7/29/93
 /CONTACT: Stephen J. Riggi, Ph.D., president & CEO, Telor Ophthalmic Pharmaceuticals, Inc., 617-937-0393; Lynne H. Brum, Feinstein Partners Inc., 617-577-8110, for Telor/
 (TELR)


CO: Telor Ophthalmic Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU:

DJ -- NE002 -- 7115 07/29/93 08:39 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 29, 1993
Words:658
Previous Article:IMMUNOGEN OPENS A NEW MANUFACTURING FACILITY IN CANTON, MASSACHUSETTS
Next Article:DURACELL ANNOUNCES RECORD EARNINGS BEFORE ACCOUNTING CHANGE AND RESTRUCTURING CHARGE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters